Theoretical lectures
Pharmacology and Toxicology 1 – Medicine 3rd year (2024.)
Wednesday: 13.30-15.45 Amph. 3
Thursday: 15.00-16.30 Amph. 2
| Lesson | Topic |
| 1 | Fundamental principles of pharmacology. Pharmacokinetics and pharmacodynamics. |
| 2 | Principles of legislation and prescribing of medicines. |
| 3 | Pharmacodynamics. |
| 4 | Receptors. |
| 5 | Relation between structure and effect of the drugs. Agonists and antagonists. |
| 6 | Down and up-regulation of receptors, and other mechanisms of receptors regulation |
| 7 | Pharmacodynamic drug interactions. Synergism and antagonism. |
| 8 | Drug dependence; classification. |
| 9 | Dosage of drugs. Doses of drugs. Therapeutic index and therapeutic window. |
| 10 | Membrane transport processes. Absorption. Factors that affect absorption. |
| 11 | Drug distribution. |
| 12 | Drug metabolism. |
| 13 | Drug excretion. |
| 14 | Importance of pharmaceutical formulations for drugs efficacy and safety. |
| 15 | Pharmacokinetic drug interactions. |
| 16 | Route of drug administration. Topical and systemic drug administration. |
| 17 | Pharmacogenomics. |
| 18 | The use of drugs during pregnancy and lactation.The influence of gender on pharmacotherapy. |
| 19 | The influence of age (elderly and children) and disease on pharmacokinetics and pharmacodynamics. |
| 20 | Adverse effects of drugs. |
| 21 | Autonomic nervous system. Cholinergic transmission. Receptors. |
| 22 | Parasympathomimetics. |
| 23 | Parasympatolytics. |
| 24 | Noradrenergic transmission. Receptors. Adrenoreceptor agonists. |
| 25 | Central sympatholytics and α1 antagonists. Beta adrenoceptor antagonists. |
| 26 | Histamine HI receptor antagonists. |
| 27 | Toxicology. |
| 28 | Toxicology. |
| 29 | Introduction to cardiology. |
| 30 | First-line drugs in the treatment of hypertension – Beta blockers, Ca channel blockers. |
| 31 | First-line drugs in the treatment of hypertension – Diuretics, ACE inhibitors, ARAs. |
| 32 | Second-line drugs in the treatment of hypertension. |
| 33 | Shock – types and therapy. |
| 34 | The treatment of angina pectoris. |
| 35 | Heart failure. |
| 36 * | Anti-arrhythmic drugs. |
| 37 * | Lipid-lowering drugs. |
| 38 * | Oral and injectable anticoagulants. Fibrinolytics. |
| 39 * | Antiplatelet agents. |
| 40 * | Anti–anemic drugs. |
| 41 * | Vitamins and minerals. |
| 42 * | Drugs that are used to treat bronchial asthma and COPD. |
| 43 * | Antitussive and mucolytic drugs Treatment of rhinitis. |
| 44 * | Peptic ulcer disease. |
| 45 * | Antiemetics. |
| 46 | Drugs in the treatment of impaired gut passage –laxatives and antidiarrheal agents. Drugs for inflammatory bowel diseases and Pseudomembranous colitis. |
| 47 | Antibacterial drugs. Classification. |
| 48 | Antimicrobial resistance and principles of antibacterial agents dosage. |
| 49 | Beta lactam antibiotics. Penicillins. |
| 50 | Cephalosporins. Beta lactamase inhibitors. Carbapenems.Monobactams. |
| 51 | Polypeptides. Glycopeptides. Lipopeptides. |
| 52 | Aminoglycosides. Tetracyclines. Glycilcyclines. |
| 53 | Macrolides. Ketolides. Lincosamides. Amphenicols. Streptogramins. Oxazolidinones. |
| 54 | Qiunolones. |
| 55 | Antibacterial azoles. Sulphonamides and trimethoprim. |
| 56 | Antifungal drugs. |
| 57 | Antituberculous drugs. |
| 58 | Antiparasitic drugs. Antimalarics. |
| 59 | Antiviral agents. |
| 60 | Anti-neoplastic drugs. |
| 61 | Immunosuppressant drugs. |
| 62 | Respiratory infections-treatment. |
| 63 | Urinary tract infections-treatment. |
| 64 | Skin and soft tissue infections – treatment. |
| 65 | Repetition (cardiology and blood disordres). |
| 66 | Repetition. (bronchial asthma). |
| 67 | Repetition. (gastrointestinal diseases). |
| 68 | Repetition. (antibiotics). |
| 69 | Repetition. |
| 70 | Repetition. |